Edition:
United Kingdom

Ambrx And Tracon Pharma Announce Commercialization Agreement For TRC105 In China


Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Tracon Pharmaceuticals Inc ::AMBRX AND TRACON PHARMACEUTICALS ANNOUNCE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR TRC105 IN CHINA.AMBRX INC - ENTERED INTO LICENSING AGREEMENT FOR DEVELOPMENT & COMMERCIALIZATION OF TRACON'S PROPRIETARY ENDOGLIN ANTIBODY, TRC105 IN CHINA.AMBRX SAYS TRANSACTION GRANTS AMBRX EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE TRC105 IN ALL INDICATIONS IN CHINA AND TAIWAN.AMBRX SAYS UNDER DEAL TERMS, TRACON WILL RECEIVE AN UPFRONT PAYMENT OF $3 MILLION.AMBRX SAYS TRACON IS ALSO ELIGIBLE TO RECEIVE TIERED ROYALTIES FROM HIGH SINGLE DIGITS TO LOW TEENS ON NET SALES OF TRC105 IN AMBRX TERRITORIES. 

Company Quote

0.5899
0.0 +0.00%
15 Jul 2019